Bimekizumab complete clearance of skin and nail psoriasis: Comparative efficacy in phase III/IIIb trials

Results from post hoc analyses of the phase III/IIIb BE SURE (NCT03412747), BE VIVID (NCT03370133), BE BRIGHT (NCT03598790), and BE RADIANT (NCT03536884) trials comparing bimekizumab with adalimumab, ustekinumab, and secukinumab for concurrent complete skin and nail clearance in patients with moderate-to-severe plaque psoriasis were recently published in the American Journal of Clinical Dermatology by Merola et al.

Key data: Bimekizumab demonstrated superior concurrent complete skin (Psoriasis Area and Severity Index [PASI] 100) and nail (modified Nail Psoriasis Severity Index [mNAPSI] 0) clearance vs active comparators: 45.8% vs 18.3% for adalimumab (BE SURE, Week 24), 51.1% vs 26.5% for ustekinumab (BE VIVID, Week 52), and 63.3% vs 36.1% for secukinumab (BE RADIANT, Week 48). Following switch to bimekizumab, clearance rates increased and were sustained long-term in both switchers and continuous bimekizumab-treated patients (sustained clearance rates of 48.3–57.7%).

Key learning: Bimekizumab’s dual interleukin (IL)-17A and IL-17F inhibition provides superior efficacy in achieving simultaneous skin and nail clearance vs adalimumab, ustekinumab, and secukinumab. The sustained long-term efficacy across multiple domains of psoriatic disease supports bimekizumab as a comprehensive treatment option for patients with moderate-to-severe plaque psoriasis requiring systemic therapy.